Finance

Beta
Lists
KAEF:IDX
Kimia Farma Tbk PT
IDR 428.00
-2.73%
(-12.00) 1D
Jun 4, 4:11:43 PM GMT+7  ·   IDR
All symbols
SymbolPriceChange% Change
Generating top insights for KAEF...
Open
IDR 440
High
IDR 444
Low
IDR 410
Mkt. cap
2.38T
Avg. vol.
8.70M
Volume
1.74M
52-wk high
IDR 785
52-wk low
IDR 410
EPS
-IDR 64
Shares outstanding
5.57B
No. of employees
10K
Open
IDR 440
High
IDR 444
Low
IDR 410
Mkt. cap
2.38T
Avg. vol.
8.70M
Volume
1.74M
52-wk high
IDR 785
52-wk low
IDR 410
EPS
-IDR 64
Shares outstanding
5.57B
No. of employees
10K
News stories
From sources across the web
Profile
PT Kimia Farma Tbk is an Indonesian pharmaceutical producer and distributor in Indonesia. It is based in Jakarta. Wikipedia
About Kimia Farma Tbk PT
CEO-
Employees9.57K
FoundedAug 16, 1971
Headquarters-
SectorPharmaceutical industry
Websitekimiafarma.co.id
Previous reportsAll values in IDR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in IDR
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
2.20T
2.64T
2.22T
2.03T
Cost of goods sold
1.45T
1.85T
1.56T
1.29T
Cost of revenue
1.45T
1.85T
1.56T
1.29T
Research and development expenses
3.90B
5.03B
7.54B
3.20B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
592.42B
709.79B
663.87B
640.94B
Operating expense
657.62B
766.80B
877.17B
669.20B
Total operating expenses
2.11T
2.62T
2.44T
1.96T
Operating income
91.07B
23.59B
-222.99B
67.93B
Other non operating income
46.72B
-2.92B
173.66B
159.00B
EBT including unusual items
7.14B
-94.33B
-223.75B
127.96B
EBT excluding unusual items
9.14B
-93.48B
-260.76B
127.95B
Income tax expense
16.32B
4.17B
-14.50B
4.32B
Effective tax rate
228.41%
-4.42%
6.48%
3.37%
Other operating expenses
-2.07B
-37.43B
-36.20B
-12.78B
Net income
7.16B
-84.72B
-155.23B
74.45B
Net profit margin
0.33%
-3.21%
-7.01%
3.67%
Earnings per share
-
-
-
-
Interest and investment income
2.27B
2.65B
10.77B
2.87B
Interest expense
-124.00B
-115.65B
-221.53B
-110.15B
Net interest expenses
-121.73B
-112.99B
-210.75B
-107.28B
Depreciation and amortization charges
63.38B
89.41B
175.98B
37.85B
EBITDA
151.36B
105.34B
-86.40B
125.64B
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer